Minoxidil

In this study, low-dose oral minoxidil and sublingual minoxidil were generally well-tolerated in children with alopecia, with mild hypertrichosis as the most common adverse event.

This study found that for people with androgenetic alopecia, increasing the dosage of low-dose oral minoxidil is associated with improvements in hair diameter and density, but also raises the risk of hypertrichosis and cardiovascular adverse events.

This study reviewed literature on low-dose oral minoxidil as a treatment for hair loss, finding good compliance and tolerability, with mild adverse effects like hypertrichosis, which increase with higher doses.

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.

This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.

This report describes a case of hypertrichosis associated with minoxidil use and suggests that nearly all patients on this drug may experience this side effect.